Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations.

被引：0
|
作者：
Chen, Monica F.
Rakhade, Swanand
Quintanal-Villalonga, Alvaro
Lee, Jake
Forsythe, Britney
Moses, Khadeja A.
Ahn, Linda Su Hyun
Pupo, Amanda
Falcon, Christina J.
Rekhtman, Natasha
Kris, Mark G.
Rudin, Charles M.
Chan, Joseph Minhow
Yu, Helena Alexandra
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Med Oncol, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8565
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical and Molecular Characteristics of EGFR Mutant Lung Cancers with Concurrent TP53 and RB1 Mutations
    Offin, M.
    Tenet, M.
    Shen, R.
    Rekhtman, N.
    Rizvi, H.
    Hellmann, M.
    Arcila, M.
    Ladanyi, M.
    Rudin, C.
    Kris, M.
    Yu, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S412 - S412
  • [2] Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
    Offin, Michael
    Chan, Joseph M.
    Tenet, Megan
    Rizvi, Hira A.
    Shen, Ronglai
    Riely, Gregory J.
    Rekhtman, Natasha
    Daneshbod, Yahya
    Quintanal-Villalonga, Alvaro
    Penson, Alexander
    Hellmann, Matthew D.
    Arcila, Maria E.
    Ladanyi, Marc
    Pe'er, Dana
    Kris, Mark G.
    Rudin, Charles M.
    Yu, Helena A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1784 - 1793
  • [3] Concurrent somatic alterations of TP53 and RB1 in Chinese lung adenocarcinoma with or without EGFR mutations.
    Wang, Jun
    Chen, Gang
    Zhang, Bicheng
    Sun, Jianguo
    Liang, Jing
    Liu, Xiaolin
    Li, Yan
    Wang, Baocheng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Genetic Characteristics of EGFR Concurrent Variants with RB1 and TP53 in NCSLC Patients
    Chen, H.
    Yuan, S.
    Chen, L.
    Shi, X.
    Wang, L.
    Dong, X.
    Wang, M.
    Wang, A.
    Liu, W.
    Cui, Z.
    Chen, C.
    Mei, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S587 - S588
  • [5] Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy
    Lu, Yiyu
    Li, Zhihua
    Zhu, Huawei
    Zhao, Juan
    Xu, Mian
    Gu, Weiguang
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (12) : 12886 - 12893
  • [6] A phase 1 study of osimertinib and bevacizumab as initial treatment for patients with EGFR-mutant lung cancers.
    Yu, Helena Alexandra
    Hayes, Sara A.
    Young, Robert J.
    Ni, Ai
    Rodriguez, Christopher
    Makhnin, Alex
    Riely, Gregory J.
    Kris, Mark G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] IDH-mutant astrocytomas with primitive neuronal component are aggressive tumors characterized by alterations in RB1 and TP53
    Slocum, C.
    Hickman, R.
    Gedvilaite, E.
    Ptashkin, R.
    Brannon, R.
    Ladanyi, M.
    Miller, A.
    Pentsova, E.
    Tabar, V.
    Young, R.
    Mellinghoff, I.
    Rosenblum, M.
    Bale, T.
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2023, 82 (06): : 522 - 523
  • [8] TP53 and RB1 alterations promote reprogramming and antiandrogen resistance in advanced prostate cancer
    Mu, Ping
    Cao, Zhen
    Hoover, Elizabeth
    Wongvipat, John
    Huang, Chun-Hao
    Karthaus, Wouter
    Abida, Wassim
    De Stanchina, Elise
    Sawyers, Charles
    [J]. CANCER RESEARCH, 2015, 75
  • [9] Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations
    Huang, J.
    Huang, W.
    Wang, Q.
    Zhang, C.
    Ni, S.
    Sun, D.
    Zhou, Y.
    Hou, T.
    Sun, W.
    Chen, Z.
    Wu, Y. -L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S48 - S48
  • [10] A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers.
    Yu, Helena Alexandra
    Kim, Rachel
    Makhnin, Alex
    Ahn, Linda Su Hyun
    Ni, Ai
    Hayes, Sara A.
    Young, Robert J.
    Riely, Gregory J.
    Kris, Mark G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345